episode 1042: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses China’s health authorities fighting surge in cases of Mpox unknown origin, analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses in primary care practices, prevalence and associated outcomes of co-infection between SARS-CoV-2 and influenza, comparison of bivalent and monovalent mRNA vaccine boosters, optimal duration of systemic corticosteroids in COVID-19 treatment, acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization, temporal changes in fecal microbiota of patients infected with COVID-19, and long-term survival after intensive care for COVID-19.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- China’s health authorities fight surge in cases of unknown origin (BMJ)
- Analysis of seasonal variation of antibiotic prescribing for respiratory tract diagnoses (ASHE)
- Prevalence and outcomes of co-infection between SARS-CoV-2 and influenza (IJID)
- Comparison of bivalent and monovalent mRNA vaccine boosters (CID)
- Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID)
- Acute blood biomarker profiles predict cognitive deficits after COVID-19 hospitalization (Nature)
- Temporal changes in fecal microbiota of patients infected with COVID-19 (BMC)
- Long-term survival after intensive care for COVID-19 (AIC)
- Contribute to our Floating Doctors fundraiser at PWB
- Letters read on TWiV 1042
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv